Ventana Medical Systems, Inc.

The University of Arizona

University of Cincinnati

Kristie A Vanpatten

Gary A Pestano

Georg F Weber

Ray B Nagle

Elizabeth Shaughnessy

Amit M Algotar

Mana Mirza

John K Hurley

Connie Cortez

The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).

Grading, staging, and prognosing cancer using osteopontin-c

The disclosure provides methods for characterizing a prostate cancer sample by detecting expression of ERG, PTEN or both, changes in which relative to a normal control are shown herein to be correlated with prostate cancer capsular penetration and more aggressive forms of prostate cancer. Such methods are useful for the prognosis of prostate cancer capsular penetration and for making treatment decisions in patients with prostate cancer that has penetrated the capsule. Also provided are kits that can be used with such methods.

Expression of ETS related gene (ERG) and phosphatase and tensin homolog (PTEN) correlates with prostate cancer capsular penetration

Grading, staging and prognosing cancer using osteopontin-C

Growing community of inventors

Oro Valley, AZ, United States of America

Kristie A Vanpatten